RxDoctor Payments Data

Patricia Hudson, MD

Urogynecology and Reconstructive Pelvic Surgery · Ephrata, PANPI 1568808566

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Valencia Technologies Corporation at 43.4% of the total. Reporting peaked in 2023 at $1,519 and has fallen 79.4% since, to $312 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in PA, where the typical reported total is $2,966.

$2,763in general payments, 2019–2025

Across 40 payments — averaging $69.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Valencia Technologies Corporation$1K
  • Medtronic$574
  • Axonics, Inc.$255
  • Astellas Pharma US Inc$232
  • Boston Scientific$176
  • AbbVie$173
  • plus $152 from 2 others

What the payments were for

  • Travel & lodging$1,25545%
  • Food & beverage$1,30847%
  • Education$2007%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,763 in reported general payments places this provider in the 45th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$95,723
Medicare patients
263
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron115$78,693
GemtesaVibegron64$64,118
Estradiol84$4,951
Methenamine Hippurate66$3,244
Trospium Chloride ErTrospium Chloride22$3,187
Trospium Chloride29$1,681
Clobetasol Propionate32$1,276
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst69$512
Fluconazole23$84
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim24$59
Cephalexin13$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$232$78,693115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

Other urogynecology and reconstructive pelvic surgery in Ephrata

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →